https://jp.gsk.com/ja-jp/ 2026-01-30T02:33:29.543Z https://jp.gsk.com/ja-jp/company/ 2025-07-30T12:04:13.29Z https://jp.gsk.com/ja-jp/company/purpose-strategy-and-culture/ 2025-11-26T07:57:29.487Z https://jp.gsk.com/ja-jp/company/at-a-glance/ 2026-04-02T01:04:20.783Z https://jp.gsk.com/ja-jp/company/at-a-glance/our-locations-en/ 2025-07-30T12:04:20.277Z https://jp.gsk.com/ja-jp/company/at-a-glance/about-imaichi-factory/ 2025-11-27T04:44:07.987Z https://jp.gsk.com/ja-jp/company/president-message/ 2025-07-30T12:04:22.683Z https://jp.gsk.com/ja-jp/company/policies-codes-and-standards/ 2025-11-26T07:58:47.623Z https://jp.gsk.com/ja-jp/innovation/ 2025-12-09T02:04:53.08Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/ 2025-07-30T12:04:58.987Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/ 2026-01-07T09:32:24.03Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/oncology/ 2026-01-15T01:04:49.5Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/hiv/ 2026-01-28T03:56:21.45Z https://jp.gsk.com/ja-jp/innovation/therapeutic-areas/infectious-diseases/ 2026-01-28T03:58:17.9Z https://jp.gsk.com/ja-jp/innovation/pipeline/ 2026-02-24T03:02:52.527Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/ 2025-12-04T01:50:41.303Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/about-trials-in-people/ 2025-07-30T12:05:07.593Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/simple-trial-data/ 2025-07-30T12:05:09.467Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/simple-trial-data/plain-language-summaries/ 2025-07-30T12:05:10.24Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/clinical-trial-information-notice/ 2025-07-30T12:05:05.693Z https://jp.gsk.com/ja-jp/innovation/trials-in-people/clinical-trials-optout/ 2025-12-04T01:49:17.167Z https://jp.gsk.com/ja-jp/products/ 2025-07-30T12:14:14.447Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/ 2026-04-01T05:48:26.437Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/adoair/ 2025-07-30T12:16:11.137Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/amerge/ 2025-07-30T12:16:06.447Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arnuity/ 2025-07-30T12:16:10.627Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/anoro/ 2025-07-30T12:16:10.087Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/avolve/ 2025-07-30T12:16:09.38Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/allermist/ 2025-07-30T12:16:05.867Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arexvy/ 2025-07-30T12:14:24.867Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/imigran/ 2025-07-30T12:16:05.343Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/volibris/ 2025-07-30T12:16:04.83Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/eskazole/ 2025-07-30T12:16:04.22Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/exdensur/ 2026-01-29T09:06:05.597Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epivir/ 2025-07-30T12:16:03.597Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epzicom/ 2025-07-30T12:16:03.017Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/encruse/ 2025-07-30T12:16:00.917Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/augmentin/ 2025-07-30T12:16:00.28Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/omjjara/ 2025-07-30T12:14:23.39Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/kindavate/ 2025-07-30T12:15:59.15Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/clavamox/ 2025-07-30T12:15:58.147Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/combivir/ 2025-07-30T12:15:55.26Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/samtirel/ 2025-07-30T12:15:51.847Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/cervarix/ 2026-04-01T05:38:38.05Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/sultanol/ 2025-12-19T03:15:42.97Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/ziagen/ 2025-07-30T12:15:54.73Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/xyzal/ 2025-07-30T12:15:54.13Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zagallo/ 2025-07-30T12:15:53.003Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/celsentri/ 2025-07-30T12:15:49.343Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/juluca/ 2025-07-30T12:15:48.217Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zyrtec/ 2025-07-30T12:15:48.797Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/shingrix/ 2025-10-22T07:49:44.407Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zefix/ 2026-02-24T02:44:26.703Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/serevent/ 2025-07-30T12:15:46.527Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zovirax/ 2026-02-12T08:33:26.583Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/duvroq/ 2026-02-24T02:43:15.603Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tenozet/ 2025-07-30T12:15:43.307Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tivicay/ 2025-07-30T12:15:42.723Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/trelegy/ 2025-07-30T12:15:42.233Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dermovate/ 2025-07-30T12:15:41.427Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dovato/ 2025-07-30T12:15:37.953Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/triumeq/ 2025-07-30T12:15:37.49Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/nucala/ 2026-03-16T05:03:47.533Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/paxil_cr/ 2025-07-30T12:15:35.623Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/bactroban/ 2025-07-30T12:15:35.13Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flutide/ 2025-07-30T12:15:30.823Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/valtrex/ 2026-02-12T08:34:23.173Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flunase/ 2026-02-06T01:44:08.233Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flolan/ 2025-07-30T12:15:29.763Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/blenrep/ 2026-03-27T01:39:06.667Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/betnevate/ 2025-07-30T12:14:21.06Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/venetlin/ 2025-07-30T12:15:29.263Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/benlysta/ 2025-07-30T12:15:28.657Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/vocabria/ 2025-07-30T12:14:26.88Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/botox/ 2025-07-30T12:15:27.997Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/malarone/ 2025-07-30T12:15:27.487Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/lamictal/ 2026-03-17T05:43:55.677Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rekambys/ 2025-07-30T12:14:25.873Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relenza/ 2026-02-03T09:07:56.89Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip/ 2026-02-24T02:45:02.63Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip_cr/ 2026-02-24T02:45:37.467Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/retrovir/ 2025-07-30T12:15:22.79Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relvar/ 2025-07-30T12:15:22.217Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rotarix/ 2025-07-30T12:15:20.29Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/adoair-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:19.723Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/amerge-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:17.157Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arnuity-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:18.653Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/anoro-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:18.163Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/avolve-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:17.697Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/allermist-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:15.13Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/arexvy-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:24.19Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/imigran-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:14.667Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/volibris-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:14.197Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/eskazole-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:13.623Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epivir-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:13.003Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/epzicom-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:12.43Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/encruse-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:11.927Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/augmentin-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:10.09Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/omjjara-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:21.55Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/kindavate-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:07.533Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/clavamox-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:06.95Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/combivir-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:06.437Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/cervarix-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:00.49Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/samtirel-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:59.967Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/sultanol-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:59.39Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/ziagen-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:05.857Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/xyzal-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:04.18Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zagallo-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:01.083Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/celsentri-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:57.677Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/juluca-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:56.243Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zyrtec-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:56.817Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/shingrix-plain-language-summaries-agreement-jp/ 2025-07-30T12:15:19.227Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zefix-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:55.733Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/serevent-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:55.23Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/zovirax-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:54.26Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/duvroq-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:51.403Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tenozet-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:50.903Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/tivicay-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:50.403Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/trelegy-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:49.757Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dermovate-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:49.287Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/dovato-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:48.793Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/triumeq-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:48.273Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/nucala-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:45.173Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/paxil_cr-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:44.243Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/bactroban-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:43.71Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/valtrex-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:43.14Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flutide-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:42.607Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flunase-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:42.087Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/blenrep-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:19.527Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/flolan-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:41.563Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/betnevate-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:20.547Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/venetlin-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:39.487Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/benlysta-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:38.823Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/vocabria-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:26.327Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/botox-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:38.31Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/malarone-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:37.77Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/lamictal-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:37.113Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rekambys-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:25.38Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relenza-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:36.243Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:33.977Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/requip_cr-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:33.377Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/retrovir-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:32.127Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/relvar-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:31.59Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/rotarix-plain-language-summaries-agreement-jp/ 2025-07-30T12:14:27.42Z https://jp.gsk.com/ja-jp/products/our-prescription-medicines/exdensur-plain-language-summaries-agreement-jp/ 2025-12-25T06:19:56.087Z https://jp.gsk.com/ja-jp/responsibility/ 2025-07-30T12:17:30.85Z https://jp.gsk.com/ja-jp/responsibility/access/ 2025-07-30T12:17:37.283Z https://jp.gsk.com/ja-jp/responsibility/global-health-and-health-security/ 2025-08-05T13:23:22.793Z https://jp.gsk.com/ja-jp/responsibility/environment/ 2026-03-10T03:52:40.983Z https://jp.gsk.com/ja-jp/responsibility/inclusion/ 2026-02-06T07:51:34.873Z https://jp.gsk.com/ja-jp/responsibility/inclusion/lgbtqplus/ 2026-03-27T08:31:05.65Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/ 2025-11-26T08:04:49.9Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-hcps/ 2025-10-01T01:01:28.63Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-hcps/about-disclosure/ 2025-07-30T12:17:45.873Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-patient-groups/ 2025-07-30T12:17:41.547Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/transparency-patient-groups/disclosure-of-financial-support/ 2025-07-30T12:17:42.133Z https://jp.gsk.com/ja-jp/responsibility/ethical-standards/efforts-to-bribery-prevention/ 2025-07-30T12:17:40.927Z https://jp.gsk.com/ja-jp/responsibility/product-governance/ 2025-07-30T12:17:31.733Z https://jp.gsk.com/ja-jp/responsibility/grants-donations/ 2025-07-30T12:17:33.43Z https://jp.gsk.com/ja-jp/responsibility/ime-grant/ 2025-07-30T12:17:51.747Z https://jp.gsk.com/ja-jp/responsibility/our-support/ 2025-07-30T12:17:54.617Z https://jp.gsk.com/ja-jp/responsibility/influenza/ 2025-07-30T12:17:39.413Z https://jp.gsk.com/ja-jp/news/ 2025-07-30T12:06:36.233Z https://jp.gsk.com/ja-jp/news/press-releases/ 2025-09-11T06:39:38.673Z https://jp.gsk.com/ja-jp/news/press-releases/20200114_rabipur-divest/ 2025-07-30T12:13:11.077Z https://jp.gsk.com/ja-jp/news/press-releases/20200120_octc/ 2025-07-30T12:13:14.857Z https://jp.gsk.com/ja-jp/news/press-releases/20200120_research_grant/ 2025-07-30T12:13:14.37Z https://jp.gsk.com/ja-jp/news/press-releases/20200212_cepi-and-gsk-announce-collaboration/ 2025-07-30T12:13:15.39Z https://jp.gsk.com/ja-jp/news/press-releases/20200217_xyzal_od_approval/ 2025-07-30T12:13:15.883Z https://jp.gsk.com/ja-jp/news/press-releases/20200221_fy2019/ 2025-07-30T12:13:16.443Z https://jp.gsk.com/ja-jp/news/press-releases/20200228_hr/ 2025-07-30T12:13:16.917Z https://jp.gsk.com/ja-jp/news/press-releases/20200302_ime_jp/ 2025-07-30T12:13:17.403Z https://jp.gsk.com/ja-jp/news/press-releases/20200303_white500_2020/ 2025-07-30T12:13:19.263Z https://jp.gsk.com/ja-jp/news/press-releases/20200304_xyzal-syrup/ 2025-07-30T12:13:20.97Z https://jp.gsk.com/ja-jp/news/press-releases/20200305_gsk-clover/ 2025-07-30T12:13:21.573Z https://jp.gsk.com/ja-jp/news/press-releases/20200323_xyzal-syrup_launch/ 2025-07-30T12:13:22.577Z https://jp.gsk.com/ja-jp/news/press-releases/20200325_nucala_pediatrics-use-approval/ 2025-07-30T12:13:22.033Z https://jp.gsk.com/ja-jp/news/press-releases/20200326_nucala_liquid-approval/ 2025-07-30T12:13:23.073Z https://jp.gsk.com/ja-jp/news/press-releases/20200420_vir-biotech_collaboration/ 2025-08-18T11:05:56.467Z https://jp.gsk.com/ja-jp/news/press-releases/20200422_sanofi_collaboration/ 2025-08-18T11:02:52.227Z https://jp.gsk.com/ja-jp/news/press-releases/20200427_gsk_micin_telemedicine/ 2025-07-30T12:13:26.13Z https://jp.gsk.com/ja-jp/news/press-releases/20200514_q12020/ 2025-07-30T12:13:26.74Z https://jp.gsk.com/ja-jp/news/press-releases/20200525_covid-19_donation/ 2025-07-30T12:13:27.257Z https://jp.gsk.com/ja-jp/news/press-releases/20200527_nucala_liquid/ 2025-07-30T12:13:27.803Z https://jp.gsk.com/ja-jp/news/press-releases/20200605_pr-1bn-doses/ 2025-07-30T12:13:28.793Z https://jp.gsk.com/ja-jp/news/press-releases/20200619_xyzal_od_launch/ 2025-07-30T12:13:28.317Z https://jp.gsk.com/ja-jp/news/press-releases/20200629_company_rule_change/ 2025-07-30T12:13:29.383Z https://jp.gsk.com/ja-jp/news/press-releases/20200629_daprodustat/ 2025-07-30T12:13:32.513Z https://jp.gsk.com/ja-jp/news/press-releases/20200702_wli/ 2025-07-30T12:13:33.29Z https://jp.gsk.com/ja-jp/news/press-releases/20200709_medicago/ 2025-07-30T12:13:34.017Z https://jp.gsk.com/ja-jp/news/press-releases/20200722_covid-19_support/ 2025-07-30T12:13:34.573Z https://jp.gsk.com/ja-jp/news/press-releases/20200806_q22020/ 2025-07-30T12:13:35.627Z https://jp.gsk.com/ja-jp/news/press-releases/20200806_re_agreement_with_kmb/ 2025-07-30T12:13:35.13Z https://jp.gsk.com/ja-jp/news/press-releases/20200807_sanofi_and_gsk/ 2025-07-30T12:13:36.12Z https://jp.gsk.com/ja-jp/news/press-releases/20200817_ocean_study/ 2025-07-30T12:13:40.36Z https://jp.gsk.com/ja-jp/news/press-releases/20200826_daprodustat_launch/ 2025-07-30T12:13:41.277Z https://jp.gsk.com/ja-jp/news/press-releases/20200901_kurumin/ 2025-07-30T12:13:41.837Z https://jp.gsk.com/ja-jp/news/press-releases/20200908_vir_biotech_clinical_trials/ 2025-07-30T12:12:27.887Z https://jp.gsk.com/ja-jp/news/press-releases/20200910_sanofi_and_gsk_clinical_trials/ 2025-07-30T12:13:44.813Z https://jp.gsk.com/ja-jp/news/press-releases/20200930_research_grant/ 2025-07-30T12:13:45.513Z https://jp.gsk.com/ja-jp/news/press-releases/20201001_patient_advocacy_activity/ 2025-07-30T12:13:46.04Z https://jp.gsk.com/ja-jp/news/press-releases/20201014_vir_biotech_p3_clinical_trials/ 2025-07-30T12:13:46.593Z https://jp.gsk.com/ja-jp/news/press-releases/20201016_ime_result/ 2025-07-30T12:13:47.127Z https://jp.gsk.com/ja-jp/news/press-releases/20201104_covax/ 2025-07-30T12:13:50.593Z https://jp.gsk.com/ja-jp/news/press-releases/20201104_hr/ 2025-07-30T12:13:47.683Z https://jp.gsk.com/ja-jp/news/press-releases/20201110_q32020/ 2025-07-30T12:13:51.973Z https://jp.gsk.com/ja-jp/news/press-releases/20201111_pride_gold/ 2025-07-30T12:13:52.623Z https://jp.gsk.com/ja-jp/news/press-releases/20201112_new_environmental_goals/ 2025-07-30T12:13:53.287Z https://jp.gsk.com/ja-jp/news/press-releases/20201119_v6_gsk-medicago_p3/ 2025-07-30T12:13:56.227Z https://jp.gsk.com/ja-jp/news/press-releases/20201127_trelegy_asthma_approval/ 2025-07-30T12:13:56.777Z https://jp.gsk.com/ja-jp/news/press-releases/20201201_hiv_test/ 2025-07-30T12:13:57.327Z https://jp.gsk.com/ja-jp/news/press-releases/20201218_sanofi_and_gsk_covid-19_vaccine_development/ 2025-07-30T12:13:57.94Z https://jp.gsk.com/ja-jp/news/press-releases/20201224_vir_biotech_p3/ 2025-07-30T12:13:58.49Z https://jp.gsk.com/ja-jp/news/press-releases/20210105_hr/ 2025-07-30T12:12:28.45Z https://jp.gsk.com/ja-jp/news/press-releases/20210119_vir-gsk_covid-19/ 2025-07-30T12:13:59.027Z https://jp.gsk.com/ja-jp/news/press-releases/20210120_research_grant/ 2025-07-30T12:14:03.133Z https://jp.gsk.com/ja-jp/news/press-releases/20210129_hr/ 2025-07-30T12:13:59.49Z https://jp.gsk.com/ja-jp/news/press-releases/20210204_lilly_vir_gsk_blaze4_trial/ 2025-07-30T12:12:34.193Z https://jp.gsk.com/ja-jp/news/press-releases/20210208_access_to_medicine/ 2025-07-30T12:12:33.673Z https://jp.gsk.com/ja-jp/news/press-releases/20210209_nagasaki_ajisai_net_ih/ 2025-07-30T12:12:32.837Z https://jp.gsk.com/ja-jp/news/press-releases/20210210_curevac_mrna_covid-19_vaccine/ 2025-07-30T12:12:30.077Z https://jp.gsk.com/ja-jp/news/press-releases/20210215_fy2020/ 2025-07-30T12:12:29.473Z https://jp.gsk.com/ja-jp/news/press-releases/20210218_trelegy_asthma_200_launch/ 2025-07-30T12:12:28.96Z https://jp.gsk.com/ja-jp/news/press-releases/20210302_sanofi-and-gsk/ 2025-07-30T12:12:27.14Z https://jp.gsk.com/ja-jp/news/press-releases/20210304_otilimab_oscar_study/ 2025-07-30T12:12:23.997Z https://jp.gsk.com/ja-jp/news/press-releases/20210310_vir_bio_and_gsk_provide_update_on_nih-sponsored_activ-3_trial_tu/ 2025-07-30T12:12:22.843Z https://jp.gsk.com/ja-jp/news/press-releases/20210315_vir_biotech_and_gsk_comet-ice_ia/ 2025-07-30T12:12:22.347Z https://jp.gsk.com/ja-jp/news/press-releases/20210323_medicago_and_gsk_starts_piii_trial/ 2025-07-30T12:12:21.757Z https://jp.gsk.com/ja-jp/news/press-releases/20210323_voli_for_pediatric_use/ 2025-07-30T12:12:21.2Z https://jp.gsk.com/ja-jp/news/press-releases/20210329_hr/ 2025-07-30T12:12:20.687Z https://jp.gsk.com/ja-jp/news/press-releases/20210406_gsk-to-support-manufacture-of-novavax-covid-19-vaccine/ 2025-07-30T12:12:18.41Z https://jp.gsk.com/ja-jp/news/press-releases/20210407_lilly-vir-biotechnology-and-gsk/ 2025-07-30T12:12:16.563Z https://jp.gsk.com/ja-jp/news/press-releases/20210421_nucala-aha/ 2025-07-30T12:12:16.1Z https://jp.gsk.com/ja-jp/news/press-releases/20210518_q12021/ 2025-07-30T12:12:15.553Z https://jp.gsk.com/ja-jp/news/press-releases/20210525_medicago-and-gsk-announce-positive-interim-phase-2/ 2025-07-30T12:12:14.52Z https://jp.gsk.com/ja-jp/news/press-releases/20210525_sanofi-and-gsk-covid-19-vaccine-p2-result/ 2025-07-30T12:12:15.03Z https://jp.gsk.com/ja-jp/news/press-releases/20210603_cop26_principal_partner/ 2025-07-30T12:12:14.057Z https://jp.gsk.com/ja-jp/news/press-releases/20210603_sanofi-gsk-covid-19-ph3-start/ 2025-07-30T12:12:13.5Z https://jp.gsk.com/ja-jp/news/press-releases/20210604_gsk-and-vir-biotechnology-announce-sotrovimab/ 2025-07-30T12:12:10.133Z https://jp.gsk.com/ja-jp/news/press-releases/20210628-comet-ice-topline-nih/ 2025-07-30T12:12:09.12Z https://jp.gsk.com/ja-jp/news/press-releases/20210701_hr/ 2025-07-30T12:12:09.613Z https://jp.gsk.com/ja-jp/news/press-releases/20210702_new-gsk/ 2025-07-30T12:12:08.587Z https://jp.gsk.com/ja-jp/news/press-releases/20210729_daprodustat_ascend/ 2025-07-30T12:12:08.107Z https://jp.gsk.com/ja-jp/news/press-releases/20210811_q22021/ 2025-07-30T12:12:07.65Z https://jp.gsk.com/ja-jp/news/press-releases/20210825_second-generation-mrna-covid-19-vaccine/ 2025-07-30T12:12:05.853Z https://jp.gsk.com/ja-jp/news/press-releases/20210831_hr/ 2025-07-30T12:12:07.093Z https://jp.gsk.com/ja-jp/news/press-releases/20210906_sotrovimab/ 2025-07-30T12:12:03.647Z https://jp.gsk.com/ja-jp/news/press-releases/20210913_vpd-ac/ 2025-07-30T12:12:04.16Z https://jp.gsk.com/ja-jp/news/press-releases/20210927_xevudy-approval/ 2025-07-30T12:12:03.173Z https://jp.gsk.com/ja-jp/news/press-releases/20211015_research_grant_result/ 2025-07-30T12:12:02.68Z https://jp.gsk.com/ja-jp/news/press-releases/20211015_gsk-welcomes-who-recommendation/ 2025-07-30T12:12:02.153Z https://jp.gsk.com/ja-jp/news/press-releases/20211028_adult_vaccination_survey_japan/ 2025-07-30T12:11:58.783Z https://jp.gsk.com/ja-jp/news/press-releases/20211101_hr/ 2025-07-30T12:12:01.643Z https://jp.gsk.com/ja-jp/news/press-releases/20211109_q32021/ 2025-07-30T12:11:57.593Z https://jp.gsk.com/ja-jp/news/press-releases/20211109_daprodustat_ascend/ 2025-07-30T12:11:57.08Z https://jp.gsk.com/ja-jp/news/press-releases/20211111_pride_gold/ 2025-07-30T12:11:56.547Z https://jp.gsk.com/ja-jp/news/press-releases/20211119_comet-tail-phase-iii/ 2025-07-30T12:11:55.953Z https://jp.gsk.com/ja-jp/news/press-releases/20211201_hiv_test/ 2025-07-30T12:11:55.47Z https://jp.gsk.com/ja-jp/news/press-releases/20211207_omicron/ 2025-07-30T12:11:54.94Z https://jp.gsk.com/ja-jp/news/press-releases/20211210_omicron/ 2025-07-30T12:11:51.87Z https://jp.gsk.com/ja-jp/news/press-releases/20211215_medicago-p3-result/ 2025-07-30T12:11:51.357Z https://jp.gsk.com/ja-jp/news/press-releases/20211221-sanofi-gsk-covid-19-booster-results/ 2025-07-30T12:11:50.82Z https://jp.gsk.com/ja-jp/news/press-releases/20220117-launch-new-oxford-gsk-institute/ 2025-07-30T12:11:50.343Z https://jp.gsk.com/ja-jp/news/press-releases/20220216_luna-sle/ 2025-07-30T12:11:49.827Z https://jp.gsk.com/ja-jp/news/press-releases/20220218_fy2021/ 2025-07-30T12:11:47.9Z https://jp.gsk.com/ja-jp/news/press-releases/20220228_taijouhoushin-yobou/ 2025-07-30T12:11:45.317Z https://jp.gsk.com/ja-jp/news/press-releases/20220303-medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz/ 2025-07-30T12:11:44.773Z https://jp.gsk.com/ja-jp/news/press-releases/20220304-sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/ 2025-07-30T12:11:44.13Z https://jp.gsk.com/ja-jp/news/press-releases/20220309_white500_2022/ 2025-07-30T12:11:43.603Z https://jp.gsk.com/ja-jp/news/press-releases/20220418-new-large-scale-observational-study/ 2025-07-30T12:11:41.96Z https://jp.gsk.com/ja-jp/news/press-releases/20220425_trait-aeris-j-study/ 2025-07-30T12:11:39.93Z https://jp.gsk.com/ja-jp/news/press-releases/20220425_copd-telemedicine-study/ 2025-07-30T12:11:39.477Z https://jp.gsk.com/ja-jp/news/press-releases/20220513_q1-2022/ 2025-07-30T12:11:38.85Z https://jp.gsk.com/ja-jp/news/press-releases/20220614-gsk-announces-positive-pivotal-phase-iii-data/ 2025-07-30T12:11:38.153Z https://jp.gsk.com/ja-jp/news/press-releases/20220628-japan-s-ministry-of-health-labour-and-welfare-accepts-shingrix-regulatory-submission-to-prevent-shingles-in-at-risk-adults-aged-18-years-and-older/ 2025-07-30T12:11:36.937Z https://jp.gsk.com/ja-jp/news/press-releases/20220701-sanofi-gsk-first-to-report/ 2025-07-30T12:11:36.067Z https://jp.gsk.com/ja-jp/news/press-releases/20220705-gsk-announces-1-billion-rd-investment-over-ten-years-to-get-ahead-of-infectious-diseases-in-lower-income-countries/ 2025-07-30T12:11:34.263Z https://jp.gsk.com/ja-jp/news/press-releases/20220712-gsk-completes-acquisition-of-sierra-oncology/ 2025-07-30T12:11:30.343Z https://jp.gsk.com/ja-jp/news/press-releases/20220713-gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/ 2025-07-30T12:11:29.81Z https://jp.gsk.com/ja-jp/news/press-releases/20220714-shingrix/ 2025-07-30T12:11:29.153Z https://jp.gsk.com/ja-jp/news/press-releases/20220725-completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/ 2025-07-30T12:11:27.223Z https://jp.gsk.com/ja-jp/news/press-releases/20220805-q2-2022/ 2025-07-30T12:11:26.36Z https://jp.gsk.com/ja-jp/news/press-releases/20220921-gsk-completes-acquisition-of-affinivax-inc/ 2025-07-30T12:11:25.097Z https://jp.gsk.com/ja-jp/news/press-releases/20220921_who-grants-prequalification-to-gsks-mosquirix_j/ 2025-07-30T12:11:22.583Z https://jp.gsk.com/ja-jp/news/press-releases/20221004-sustainable-procurement-programme/ 2025-07-30T12:11:20.287Z https://jp.gsk.com/ja-jp/news/press-releases/20221006-disease-surveillance-project-in-nepal-with-microsoft/ 2025-07-30T12:11:19.497Z https://jp.gsk.com/ja-jp/news/press-releases/20221013-telemedicine-seminar/ 2025-07-30T12:11:18.01Z https://jp.gsk.com/ja-jp/news/press-releases/20221017-gsks-older-adult-respiratory-syncytial-virus-rsv-vaccine-candidate/ 2025-07-30T12:11:15.48Z https://jp.gsk.com/ja-jp/news/press-releases/20221020-new-data-show-shingrix-can-provide-at-least-10-years-of-protection-against-shingles-in-adults-aged-50-years-and-over/ 2025-07-30T12:11:14.457Z https://jp.gsk.com/ja-jp/news/press-releases/20221021-rsv-vaccine-candidate/ 2025-07-30T12:11:10.24Z https://jp.gsk.com/ja-jp/news/press-releases/20221031-gsk-reports-outcome-from-us-fda-advisory-committee-meeting-on-daprodustat-for-anaemia-of-ckd/ 2025-07-30T12:11:08.13Z https://jp.gsk.com/ja-jp/news/press-releases/20221101-hr/ 2025-07-30T12:11:07.58Z https://jp.gsk.com/ja-jp/news/press-releases/20221104-gsk-marketing-authorisation-application-for-respiratory-syncytial-virus-older-adult-vaccine-candidate-accepted-by-european-medicines-agency-under-accelerated-assessment/ 2025-07-30T12:11:05.447Z https://jp.gsk.com/ja-jp/news/press-releases/20221109-gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-granted-priority-review-by-us-fda/ 2025-07-30T12:11:03.43Z https://jp.gsk.com/ja-jp/news/press-releases/20221110-pride-gold/ 2025-07-30T12:11:02.887Z https://jp.gsk.com/ja-jp/news/press-releases/20221111-q3-2022/ 2025-07-30T12:11:00.807Z https://jp.gsk.com/ja-jp/news/press-releases/20221117-gsk-announces-phase-iii-trials-for-gepotidacin/ 2025-07-30T12:11:00.253Z https://jp.gsk.com/ja-jp/news/press-releases/20221118-sanofi-and-gsks-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-ec/ 2025-07-30T12:10:59.097Z https://jp.gsk.com/ja-jp/news/press-releases/20221121-nucala-ped-launch/ 2025-07-30T12:10:56.22Z https://jp.gsk.com/ja-jp/news/press-releases/20221128-gsk-tops-access-to-medicine-index-atmi-for-eighth-consecutive-time/ 2025-07-30T12:10:55.723Z https://jp.gsk.com/ja-jp/news/press-releases/20230106-hr/ 2025-07-30T12:10:55.237Z https://jp.gsk.com/ja-jp/news/press-releases/20230210-jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/ 2025-07-31T16:46:35.597Z https://jp.gsk.com/ja-jp/news/press-releases/20230210-fy2022/ 2025-07-31T16:46:57.437Z https://jp.gsk.com/ja-jp/news/press-releases/20230214-benlysta-granted-orphan-drug-designation-by-us-fda-for-the-potential-treatment-of-systemic-sclerosis/ 2025-07-31T16:47:17.59Z https://jp.gsk.com/ja-jp/news/press-releases/20230216-landmark-new-england-journal-of-medicine-publication-reinforces-potential-of-gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate/ 2025-08-18T10:56:58.153Z https://jp.gsk.com/ja-jp/news/press-releases/20230227_taijouhoushin-yobou/ 2025-07-30T12:10:50.467Z https://jp.gsk.com/ja-jp/news/press-releases/20230228_sle/ 2025-07-30T12:10:49.83Z https://jp.gsk.com/ja-jp/news/press-releases/20230307-us-fda-advisory-committee-votes-to-support-effectiveness-and-safety-of-gsk-s-rsv-older-adult-vaccine-candidate/ 2025-08-18T10:49:08.343Z https://jp.gsk.com/ja-jp/news/press-releases/20230331-hr/ 2025-07-30T12:10:47.827Z https://jp.gsk.com/ja-jp/news/press-releases/20230424-egpa/ 2025-07-30T12:10:46.193Z https://jp.gsk.com/ja-jp/news/press-releases/20230427-gepotidacins-positive-phase-iii-data-shows-potential-to-be-the-first-in-a-new-class-of-oral-antibiotics-for-uncomplicated-urinary-tract-infections/ 2025-07-31T16:49:30.383Z https://jp.gsk.com/ja-jp/news/press-releases/20230508-gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-gains-positive-european-medicines-agency-chmp-opinion/ 2025-08-18T10:46:55.377Z https://jp.gsk.com/ja-jp/news/press-releases/20230509-us-fda-approves-gsks-arexvy-the-worlds-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-07-31T16:49:59.213Z https://jp.gsk.com/ja-jp/news/press-releases/20230510_asthma/ 2025-07-30T12:10:41.743Z https://jp.gsk.com/ja-jp/news/press-releases/20230512_q1-2023/ 2025-07-31T16:50:20.63Z https://jp.gsk.com/ja-jp/news/press-releases/20230614-european-commission-authorises-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-07-31T16:50:42.6Z https://jp.gsk.com/ja-jp/news/press-releases/20230615-personnel-system/ 2025-07-30T12:10:37.72Z https://jp.gsk.com/ja-jp/news/press-releases/20230626-shingrix/ 2025-07-30T12:10:35.607Z https://jp.gsk.com/ja-jp/news/press-releases/20230628-cdc-and-prevention-acip-votes-to-recommend-arexvy/ 2025-07-31T16:51:04.997Z https://jp.gsk.com/ja-jp/news/press-releases/20230706-gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/ 2025-07-31T16:51:17.67Z https://jp.gsk.com/ja-jp/news/press-releases/20230712-gsk-completes-acquisition-of-bellus-health/ 2025-07-30T12:10:32.607Z https://jp.gsk.com/ja-jp/news/press-releases/20230720_taijouhoushin-yobou-tvcm/ 2025-07-30T12:10:29.267Z https://jp.gsk.com/ja-jp/news/press-releases/20230728-medicines-and-healthcare-products-regulatory-agency-authorises-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-08-18T08:57:48.557Z https://jp.gsk.com/ja-jp/news/press-releases/20230803_q2-2023/ 2025-07-31T16:52:05.533Z https://jp.gsk.com/ja-jp/news/press-releases/20230904-gsks-regulatory-submission-accepted-for-review-by-japanese-regulator-for-use-of-nucala-mepolizumab/ 2025-07-30T12:10:23.77Z https://jp.gsk.com/ja-jp/news/press-releases/20230907-new-shingrix-data-demonstrate-100-vaccine-efficacy-in-prevention-shingles/ 2025-07-30T12:10:23.18Z https://jp.gsk.com/ja-jp/news/press-releases/20230911-gsk-regulatory-submission-for-momelotinib-for-the-treatment-of-myelofibrosis-accepted-for-review-by-japanese-regulator/ 2025-07-30T12:10:22.66Z https://jp.gsk.com/ja-jp/news/press-releases/20230925-arexvy/ 2025-07-31T16:53:14.613Z https://jp.gsk.com/ja-jp/news/press-releases/20230929-kyushu-university/ 2025-07-31T16:53:31.133Z https://jp.gsk.com/ja-jp/news/press-releases/20231002-ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/ 2025-07-30T12:10:20.95Z https://jp.gsk.com/ja-jp/news/press-releases/20231016-zensokujp/ 2025-07-30T12:10:26.787Z https://jp.gsk.com/ja-jp/news/press-releases/20231019-gsk-and-viiv-healthcare-to-present-scientific-advancements-at-idweek-2023/ 2025-07-30T12:10:20.393Z https://jp.gsk.com/ja-jp/news/press-releases/20231023-gsk-and-save-the-children-renew-award-winning-partnership/ 2025-07-30T12:10:18.007Z https://jp.gsk.com/ja-jp/news/press-releases/20231026-lgbtqplus/ 2025-07-31T16:54:12.693Z https://jp.gsk.com/ja-jp/news/press-releases/20231031-new-data-for-arexvy-show-potential-to-help-protect-adults-aged-50-to-59/ 2025-07-30T12:10:16.657Z https://jp.gsk.com/ja-jp/news/press-releases/20231107-pride-gold/ 2025-07-31T16:54:40.113Z https://jp.gsk.com/ja-jp/news/press-releases/20231109_q3-2023/ 2025-07-31T16:54:54.623Z https://jp.gsk.com/ja-jp/news/press-releases/20231110-gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089/ 2025-07-30T12:10:13.553Z https://jp.gsk.com/ja-jp/news/press-releases/20231117-arexvy-rsv-vaccine-the-best-inventions-of-2023/ 2025-07-31T16:55:15.393Z https://jp.gsk.com/ja-jp/news/press-releases/20231130-gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/ 2025-07-30T12:10:10.403Z https://jp.gsk.com/ja-jp/news/press-releases/20231206-egpa/ 2025-07-30T12:10:09.823Z https://jp.gsk.com/ja-jp/news/press-releases/20231212-arexvy-rsv-vaccine/ 2025-07-31T16:55:47.427Z https://jp.gsk.com/ja-jp/news/press-releases/20231213-new-global-survey-finds-widespread-misunderstandings-about-shingles-despite-its-lifetime-prevalence/ 2025-08-18T10:42:14.22Z https://jp.gsk.com/ja-jp/news/press-releases/20231215-gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/ 2025-07-30T12:10:08.073Z https://jp.gsk.com/ja-jp/news/press-releases/20240110-rsvirus/ 2025-07-31T16:21:54.633Z https://jp.gsk.com/ja-jp/news/press-releases/20240115-arexvy/ 2025-07-31T16:22:19.293Z https://jp.gsk.com/ja-jp/news/press-releases/20240116-support/ 2025-07-31T16:22:59.817Z https://jp.gsk.com/ja-jp/news/press-releases/20240117-gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/ 2025-07-31T16:23:45.617Z https://jp.gsk.com/ja-jp/news/press-releases/20240124-rsvirus/ 2025-07-30T12:10:00.023Z https://jp.gsk.com/ja-jp/news/press-releases/20240129-gsk-enters-agreement-to-acquire-aiolos-bio/ 2025-07-30T12:09:58.237Z https://jp.gsk.com/ja-jp/news/press-releases/20240205-shibukawa-city/ 2025-07-30T12:09:55.073Z https://jp.gsk.com/ja-jp/news/press-releases/20240207-arexvy-accepted-for-regulatory-review-by-ema-for-prevention-of-rsv-in-adults-50-59/ 2025-07-30T12:09:54.53Z https://jp.gsk.com/ja-jp/news/press-releases/20240209-fy2023/ 2025-07-31T16:25:13.233Z https://jp.gsk.com/ja-jp/news/press-releases/20240213-arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2025-07-30T12:09:53.277Z https://jp.gsk.com/ja-jp/news/press-releases/20240219-european-commission-authorises-gsks-omjjara-momelotinib/ 2025-07-30T12:09:50.65Z https://jp.gsk.com/ja-jp/news/press-releases/20240222-taijouhoushin-yobou/ 2025-07-30T12:09:48.78Z https://jp.gsk.com/ja-jp/news/press-releases/20240228-dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/ 2025-08-18T10:35:47.013Z https://jp.gsk.com/ja-jp/news/press-releases/20240301-hr/ 2025-07-30T12:09:47.68Z https://jp.gsk.com/ja-jp/news/press-releases/20240329-gsk-announces-positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma/ 2025-08-18T10:33:37.123Z https://jp.gsk.com/ja-jp/news/press-releases/20240401-hr/ 2025-07-30T12:09:47.21Z https://jp.gsk.com/ja-jp/news/press-releases/20240410-rsvirus/ 2025-07-30T12:09:46.093Z https://jp.gsk.com/ja-jp/news/press-releases/20240418-new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/ 2025-07-30T12:09:41.89Z https://jp.gsk.com/ja-jp/news/press-releases/20240425-eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc/ 2025-08-18T10:20:43.49Z https://jp.gsk.com/ja-jp/news/press-releases/20240509-tomonin/ 2025-07-31T16:27:21.837Z https://jp.gsk.com/ja-jp/news/press-releases/20240510-fda-accepts-gsk-application-expanded-indication-of-jemperli-dostarlimab-plus-chemotherapy-include-all-adult-patients-primary-advanced-recurrent-endometrial-cancer/ 2025-07-31T16:27:47.63Z https://jp.gsk.com/ja-jp/news/press-releases/20240514-rsvirus/ 2025-07-31T16:28:06.843Z https://jp.gsk.com/ja-jp/news/press-releases/20240514-rsvirus-tvcm/ 2025-07-31T16:28:22.77Z https://jp.gsk.com/ja-jp/news/press-releases/20240514-rsvirus-yobou-project/ 2025-07-31T16:28:40.657Z https://jp.gsk.com/ja-jp/news/press-releases/20240515_q1-2024/ 2025-07-31T16:28:54.153Z https://jp.gsk.com/ja-jp/news/press-releases/20240530-gsk-to-become-a-founding-partner-of-fleming-initiative-to-fight-antimicrobial-resistance-amr/ 2025-08-18T10:34:42.347Z https://jp.gsk.com/ja-jp/news/press-releases/20240603-gsk-announces-positive-results-from-phase-iii-severe-asthma-trials-of-depemokimab/ 2025-07-31T16:29:23.323Z https://jp.gsk.com/ja-jp/news/press-releases/20240610-us-fda-approves-expanded-age-indication-for-gsks-arexvy-the-first-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2025-07-31T16:29:35.773Z https://jp.gsk.com/ja-jp/news/press-releases/20240612-blenrep-combination-reduced-the-risk-of-disease-progression/ 2025-08-18T09:00:24.063Z https://jp.gsk.com/ja-jp/news/press-releases/20240614-jemperli-dostarlimab-trial-continues-to-show-unprecedented-results/ 2025-07-31T16:30:07.067Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-benlysta/ 2026-02-02T02:12:46.027Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-botox/ 2025-07-31T16:30:20.433Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-relvar/ 2025-07-31T16:30:33.213Z https://jp.gsk.com/ja-jp/news/press-releases/20240624-omjjara/ 2025-07-31T16:31:00.753Z https://jp.gsk.com/ja-jp/news/press-releases/20240705-jemperli-dostarlimab-plus-chemotherapy-application-accepted-for-review-by-ema/ 2025-07-31T16:32:03.81Z https://jp.gsk.com/ja-jp/news/press-releases/20240802-blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency/ 2025-07-31T16:32:21.583Z https://jp.gsk.com/ja-jp/news/press-releases/20240809_q2-2024/ 2025-07-31T16:32:48.967Z https://jp.gsk.com/ja-jp/news/press-releases/20240815-omjjara/ 2025-07-30T12:09:16.263Z https://jp.gsk.com/ja-jp/news/press-releases/20240819_taijouhoushin-yobou-tvcm/ 2025-07-31T16:34:35.467Z https://jp.gsk.com/ja-jp/news/press-releases/20240821-micin-miroha/ 2025-07-31T16:34:58.87Z https://jp.gsk.com/ja-jp/news/press-releases/20240822-every-study/ 2025-07-31T16:35:12.02Z https://jp.gsk.com/ja-jp/news/press-releases/20240822-us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-07-31T16:39:02.137Z https://jp.gsk.com/ja-jp/news/press-releases/20240823-relvar/ 2025-07-30T12:09:14.34Z https://jp.gsk.com/ja-jp/news/press-releases/20240828-nucala/ 2025-07-31T16:38:47.783Z https://jp.gsk.com/ja-jp/news/press-releases/20240828-bepirovirsen/ 2025-07-31T16:38:34.66Z https://jp.gsk.com/ja-jp/news/press-releases/20240905-european-commission-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2025-07-31T16:38:20.87Z https://jp.gsk.com/ja-jp/news/press-releases/20240917-blenrep-belantamab-mafodotin/ 2025-07-31T16:38:06.787Z https://jp.gsk.com/ja-jp/news/press-releases/20240924-global-rsv-awareness-week/ 2025-07-31T16:37:53.26Z https://jp.gsk.com/ja-jp/news/press-releases/20240926-ckd/ 2025-07-31T16:40:29.703Z https://jp.gsk.com/ja-jp/news/press-releases/20241004-arexvy-shingrix/ 2025-07-31T16:40:45.623Z https://jp.gsk.com/ja-jp/news/press-releases/20241011-gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/ 2025-07-31T16:40:59.257Z https://jp.gsk.com/ja-jp/news/press-releases/20241025-gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents/ 2025-07-31T16:41:10.06Z https://jp.gsk.com/ja-jp/news/press-releases/20241028-gsk-announces-positive-phase-iii-results-from-anchor-trials/ 2025-07-31T16:41:22.53Z https://jp.gsk.com/ja-jp/news/press-releases/20241101-2024kenkokaigi/ 2025-07-31T16:41:34.297Z https://jp.gsk.com/ja-jp/news/press-releases/20241108-new-data-for-arexvy-show-potential-to-help-protect-a-broader-group-of-adults-at-increased-risk-for-rsv-disease/ 2025-07-31T16:41:46.403Z https://jp.gsk.com/ja-jp/news/press-releases/20241111_q3-2024/ 2025-07-31T16:42:04.397Z https://jp.gsk.com/ja-jp/news/press-releases/20241119-pride_gold_rainbow/ 2025-07-31T16:42:18.897Z https://jp.gsk.com/ja-jp/news/press-releases/20241122-arexvy/ 2025-07-31T16:42:32.557Z https://jp.gsk.com/ja-jp/news/press-releases/20241127-blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-relapsedrefractory-multiple-myeloma/ 2025-07-31T16:42:44.21Z https://jp.gsk.com/ja-jp/news/press-releases/20241203-linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus/ 2025-07-31T16:43:08.943Z https://jp.gsk.com/ja-jp/news/press-releases/20241204-statement-gsk-continues-to-show-strong-leadership-in-its-access-to-medicines-index-ranking/ 2025-07-31T16:42:56.21Z https://jp.gsk.com/ja-jp/news/press-releases/20241205-blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-07-31T16:43:22.963Z https://jp.gsk.com/ja-jp/news/press-releases/20241218-blenrep-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse/ 2025-07-31T16:43:38.327Z https://jp.gsk.com/ja-jp/news/press-releases/20241218-shingrix/ 2025-07-31T10:26:56.947Z https://jp.gsk.com/ja-jp/news/press-releases/20241220-jemperli-dostarlimab-plus-chemotherapy-receives-positive-chmp-opinion-to-expand-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-07-31T16:43:54.793Z https://jp.gsk.com/ja-jp/news/press-releases/20241223-jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/ 2025-07-31T16:44:08.863Z https://jp.gsk.com/ja-jp/news/press-releases/20241224-b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/ 2025-07-31T16:44:22.037Z https://jp.gsk.com/ja-jp/news/press-releases/20250128-depemokimab/ 2025-07-31T16:13:03.85Z https://jp.gsk.com/ja-jp/news/press-releases/20250131-european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-07-31T16:13:20.787Z https://jp.gsk.com/ja-jp/news/press-releases/20250217-fy2024/ 2025-07-31T16:13:48.733Z https://jp.gsk.com/ja-jp/news/press-releases/20250310-depemokimab-applications-accepted-for-review-by-the-us-fda/ 2025-07-31T16:14:04.553Z https://jp.gsk.com/ja-jp/news/press-releases/20250314-depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp/ 2025-07-31T16:14:22.34Z https://jp.gsk.com/ja-jp/news/press-releases/20250401-shingrix/ 2025-07-31T10:24:05.823Z https://jp.gsk.com/ja-jp/news/press-releases/20250414-blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/ 2025-07-31T16:14:39.707Z https://jp.gsk.com/ja-jp/news/press-releases/20250425-arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices/ 2025-07-31T16:14:54.783Z https://jp.gsk.com/ja-jp/news/press-releases/20250430-blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma/ 2025-07-31T16:15:42.647Z https://jp.gsk.com/ja-jp/news/press-releases/20250514_q1-2025/ 2025-07-31T16:15:58.01Z https://jp.gsk.com/ja-jp/news/press-releases/20250520-hr/ 2025-07-31T16:16:26.04Z https://jp.gsk.com/ja-jp/news/press-releases/20250519-blenrep/ 2026-03-17T10:17:36.223Z https://jp.gsk.com/ja-jp/news/press-releases/20250521-glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus/ 2025-07-31T16:16:39.813Z https://jp.gsk.com/ja-jp/news/press-releases/20250602_taijouhoushin-yobou-cp/ 2025-07-31T16:17:18.033Z https://jp.gsk.com/ja-jp/news/press-releases/20250612-linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda/ 2025-07-31T16:17:31.84Z https://jp.gsk.com/ja-jp/news/press-releases/20250618-gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/ 2025-07-31T16:17:43.663Z https://jp.gsk.com/ja-jp/news/press-releases/20250620-japan-s-mhlw-accepts-regulatory-application-to-expand-use-of-gsk-s-rsv-vaccine-arexvy-in-adults-aged-18-49-at-increased-risk-of-severe-rsv-disease/ 2025-07-31T16:17:55.87Z https://jp.gsk.com/ja-jp/news/press-releases/20250630-linerixibat-accepted-for-review-by-the-european-medicines-agency/ 2025-07-31T16:18:18.89Z https://jp.gsk.com/ja-jp/news/press-releases/20250701-hr/ 2025-07-31T16:18:07Z https://jp.gsk.com/ja-jp/news/press-releases/20250716-gsk-completes-acquisition-of-efimosfermin/ 2025-07-31T16:18:50.713Z https://jp.gsk.com/ja-jp/news/press-releases/20250717-price-of-world-s-first-malaria-vaccine-rts-s-for-children-in-endemic-countries-to-be-reduced/ 2025-07-31T16:18:33.843Z https://jp.gsk.com/ja-jp/news/press-releases/20250801-hr/ 2025-07-31T16:19:02.533Z https://jp.gsk.com/ja-jp/news/press-releases/20250723-us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine/ 2025-07-31T16:19:15.787Z https://jp.gsk.com/ja-jp/news/press-releases/20250731-blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-08-07T08:18:21.633Z https://jp.gsk.com/ja-jp/news/press-releases/20250731-gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsedrefractory-multiple-myeloma/ 2025-08-11T10:10:25.16Z https://jp.gsk.com/ja-jp/news/press-releases/20250808_q2-2025/ 2025-11-07T05:29:56.587Z https://jp.gsk.com/ja-jp/news/press-releases/20231226-jemperli-plus-chemotherapy-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union/ 2025-08-11T13:18:10.99Z https://jp.gsk.com/ja-jp/news/press-releases/20250827-gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea/ 2025-08-27T09:12:01.287Z https://jp.gsk.com/ja-jp/news/press-releases/20250904-hr/ 2025-09-11T06:34:40.163Z https://jp.gsk.com/ja-jp/news/press-releases/20250929-gsk-to-invest-30-billion-in-rd-and-manufacturing-in-the-united-states-over-next-5-years/ 2025-09-29T05:00:15.353Z https://jp.gsk.com/ja-jp/news/press-releases/20251006-luke-miels-appointed-ceo-designate-for-gsk/ 2025-10-06T05:00:24.63Z https://jp.gsk.com/ja-jp/news/press-releases/20251110_q3-2025/ 2025-11-10T04:00:50.953Z https://jp.gsk.com/ja-jp/news/press-releases/20251117-pride_gold/ 2025-11-17T01:11:19.697Z https://jp.gsk.com/ja-jp/news/press-releases/20260105-hr/ 2026-01-05T05:03:52.97Z https://jp.gsk.com/ja-jp/news/press-releases/20251222-exdensur/ 2026-02-19T05:03:02.367Z https://jp.gsk.com/ja-jp/news/press-releases/20260202-hr/ 2026-02-02T01:54:59.047Z https://jp.gsk.com/ja-jp/news/press-releases/20260213_fy2025/ 2026-02-13T05:00:37.657Z https://jp.gsk.com/ja-jp/news/press-releases/20260226-bepirovirsen/ 2026-02-26T07:10:10.183Z https://jp.gsk.com/ja-jp/news/press-releases/20260318-blenrep_japan_launch/ 2026-03-18T02:00:14.833Z https://jp.gsk.com/ja-jp/news/press-releases/20260325-risvutatug-rezetecan/ 2026-03-25T02:04:14.517Z https://jp.gsk.com/ja-jp/news/media-contacts/ 2025-07-30T12:07:45.337Z https://jp.gsk.com/ja-jp/news/healthcare-professionals/ 2025-07-30T12:06:46.82Z https://jp.gsk.com/ja-jp/news/healthcare-professionals/202504-jpseibutsuyurai/ 2026-03-18T08:21:38.167Z https://jp.gsk.com/ja-jp/news/consumers/ 2025-07-31T15:36:40.757Z https://jp.gsk.com/ja-jp/news/consumers/2015-02-04/ 2025-07-30T12:06:48.847Z https://jp.gsk.com/ja-jp/news/consumers/2015-02-04-02/ 2025-07-30T12:06:49.747Z https://jp.gsk.com/ja-jp/news/consumers/2015-03-03-01/ 2025-07-30T12:06:52.6Z https://jp.gsk.com/ja-jp/news/consumers/2015-03-03-02/ 2025-07-30T12:06:53.44Z https://jp.gsk.com/ja-jp/news/consumers/2015-03-03-03/ 2025-07-30T12:06:54.167Z https://jp.gsk.com/ja-jp/news/consumers/2015-09-02/ 2025-07-30T12:06:57.977Z https://jp.gsk.com/ja-jp/news/consumers/2015-09-30/ 2025-07-30T12:06:58.82Z https://jp.gsk.com/ja-jp/news/consumers/2015-10-19/ 2025-07-30T12:07:00.273Z https://jp.gsk.com/ja-jp/news/consumers/2016-03-14/ 2025-07-30T12:07:00.877Z https://jp.gsk.com/ja-jp/news/consumers/2016-04-04/ 2025-07-30T12:07:03.763Z https://jp.gsk.com/ja-jp/news/consumers/2016-04-25/ 2025-07-30T12:07:07.263Z https://jp.gsk.com/ja-jp/news/consumers/2016-07-27/ 2025-07-30T12:07:08.163Z https://jp.gsk.com/ja-jp/news/consumers/2019-10-10/ 2025-07-30T12:07:10.093Z https://jp.gsk.com/ja-jp/news/consumers/2019-10-10-02/ 2025-07-31T09:07:13.673Z https://jp.gsk.com/ja-jp/news/consumers/2019-10-16/ 2025-07-30T12:07:08.793Z https://jp.gsk.com/ja-jp/news/consumers/2020-06-30/ 2025-07-31T10:16:20.71Z https://jp.gsk.com/ja-jp/news/consumers/2020-10-01/ 2025-07-30T12:07:14.317Z https://jp.gsk.com/ja-jp/news/responsibility-news/ 2025-07-31T15:36:50.853Z https://jp.gsk.com/ja-jp/news/in-focus/ 2025-07-30T12:06:39.04Z https://jp.gsk.com/ja-jp/news/in-focus/disease-information/ 2026-04-01T05:40:12.667Z https://jp.gsk.com/ja-jp/news/our-social-media/ 2025-07-30T12:06:37.13Z https://jp.gsk.com/ja-jp/careers/ 2025-12-24T04:04:52.213Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/ 2025-11-26T08:08:31.493Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/developing-our-people/ 2025-07-30T12:05:49.703Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/emploee-health-safety-and-well-being/ 2025-10-30T05:55:20.677Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/rewarding-performance/ 2025-07-30T12:05:47.64Z https://jp.gsk.com/ja-jp/careers/life-at-gsk/personnel-system/ 2025-07-30T12:05:47.027Z https://jp.gsk.com/ja-jp/careers/experienced-professionals/ 2025-07-30T12:06:11.85Z https://jp.gsk.com/ja-jp/careers/recruitment/ 2025-12-24T04:00:21.357Z https://jp.gsk.com/ja-jp/careers/message/ 2025-12-26T01:38:02.597Z https://jp.gsk.com/ja-jp/careers/our-people-interview/ 2025-11-10T03:45:33.073Z https://jp.gsk.com/ja-jp/careers/our-people-interview/oncology-medical-project-manager/ 2025-07-30T12:05:35.737Z https://jp.gsk.com/ja-jp/careers/our-people-interview/oncology-senior-clinical-scientist/ 2025-07-30T12:05:35.037Z https://jp.gsk.com/ja-jp/careers/our-people-interview/consumer-engagement-manager/ 2025-07-30T12:05:36.37Z https://jp.gsk.com/ja-jp/careers/our-people-interview/vaccine-mr/ 2025-07-30T12:05:34.21Z https://jp.gsk.com/ja-jp/careers/our-people-interview/vaccine-manager/ 2025-07-30T12:05:33.53Z https://jp.gsk.com/ja-jp/careers/our-people-interview/vaccine-medical-advisor-02/ 2025-07-30T12:05:29.827Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-quality-control/ 2025-11-10T03:34:38.393Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-quality-assurance/ 2025-11-10T03:35:28.403Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-product-lifecycle-lead/ 2025-11-10T03:36:14.93Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-group-manager/ 2025-11-10T03:36:52.62Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-site-director/ 2025-11-10T03:37:28.997Z https://jp.gsk.com/ja-jp/careers/our-people-interview/imaichi-documentation-officer/ 2025-11-10T03:38:09.473Z https://jp.gsk.com/ja-jp/contact-us/ 2025-07-30T12:06:25.153Z https://jp.gsk.com/ja-jp/contact-us/healthcare/ 2026-01-04T23:56:06.523Z https://jp.gsk.com/ja-jp/contact-us/vaccine/ 2025-07-30T12:06:29.373Z https://jp.gsk.com/ja-jp/contact-us/careers/ 2025-07-30T12:06:28.04Z https://jp.gsk.com/ja-jp/contact-us/others/ 2025-07-30T12:06:26.583Z https://jp.gsk.com/ja-jp/locations/ 2025-08-11T14:19:36.783Z https://jp.gsk.com/ja-jp/terms-of-use/ 2025-07-30T12:17:30.217Z https://jp.gsk.com/ja-jp/cookie-policy/ 2025-07-30T12:17:24.557Z https://jp.gsk.com/ja-jp/accessibility/ 2025-08-18T09:09:01.71Z https://jp.gsk.com/ja-jp/digital-sustainability/ 2025-07-30T12:04:11.827Z https://jp.gsk.com/ja-jp/privacy-policy/ 2025-07-30T12:17:25.06Z https://jp.gsk.com/ja-jp/privacy-policy/privacy02/ 2025-07-30T12:17:25.587Z https://jp.gsk.com/ja-jp/sitemap/ 2025-07-31T15:35:08.163Z https://jp.gsk.com/ja-jp/search/ 2025-07-31T15:52:17.473Z https://jp.gsk.com/ja-jp/error-404/ 2025-07-31T15:33:35.447Z